Abstract: Described are improved methods for treating solid tumors, such as malignant gliomas, with a dual approach utilizing a CAR-T immunotherapy and a viral oncolytic therapy.
Type:
Application
Filed:
September 9, 2021
Publication date:
March 10, 2022
Applicants:
Mustang Bio, Inc., Beckman Research Institute of the City of Hope
Inventors:
Knut Niss, Sadik H. Kassim, Christine E. Brown, Stephen J. Forman, Behnam Badie
Abstract: The present disclosure relates generally to antibodies and binding fragments thereof that bind to anti-CD123 antibodies, chimeric antigen receptors (CARs), or antibody binding fragments. In particular, the disclosed anti-idiotype antibodies and fragments bind to anti-CD123 antibodies, CARs, or fragments thereof and comprise novel complementary determining regions (CDRs). Finally, the present disclosure relates to methods of using the disclosed antibodies and fragments thereof to expand and/or activate CD123-CAR-expressing immune cells, detecting or quantifying CD123-CARs, and isolating CD123-CAR-expressing immune cells.
Type:
Application
Filed:
March 3, 2021
Publication date:
September 9, 2021
Applicant:
Mustang Bio, Inc.
Inventors:
Ekta PATEL, Junxia WANG, Ajit KAMATH, Nathan K GUMLAW
Abstract: The present disclosure relates generally to methods treatment of hematological cancers, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), or Myelodysplastic Syndrome (MDS), comprising a combination of decitabine and a CD123-targeted therapy. In particular, the disclosed methods involve pretreatment of a patient with decitabine prior to administration of a CD123-targeted therapy.
Type:
Application
Filed:
November 27, 2019
Publication date:
July 16, 2020
Applicants:
Mustang Bio, Inc., City of Hope
Inventors:
Pam Cohen, Sadik Kassim, Ekta Patel, Elizabeth Budde, Stephen J. Forman
Abstract: The present disclosure relates generally to methods for preparing cell-based therapeutic compositions for treating hematological cancers. In particular, the disclosure relates to depleting CD56+ cells from cell-based therapeutics used to treat hematological cancers.